As much as twenty states had filed a lawsuit against drug makers: Mylan, Teva Pharmaceuticals, Heritage Pharmaceuticals Inc., Mayne Pharma, Aurobindo Pharma, and Citron Pharma LLC. The civil lawsuit is one piece of a broader generic drug pricing probe that remains under way at the state and federal level, as well as in the U.S. Congress. The investigations have developed over the past two years to contain multiple drugs and companies, some of which have disclosed they are being examined by the Department of Justice.
The lawsuit, filed in the U.S. District Court for the District of Connecticut, names Heritage Pharmaceuticals Inc. as the operation “ring leader”. According to Reuters, the drugs involved in Thursday’s lawsuit include the delayed release version of a common antibiotic, doxycycline hyclate; and glyburide, an older drug used to treat diabetes. Asked for comment on Thursday, a spokesman for Heritage referred to their comment from the previous day, which blamed the former executives for the price-fixing and said that they had been terminated. Heritage is part of Indian company Emcure Pharmaceuticals.
Mylan denied the charge. “To date, we know of no evidence that Mylan participated in price fixing,” Mylan spokeswoman Nina Devlin said by email. Teva spokeswoman Denise Bradley said by email that the company had just received the complaint and was reviewing it. The other three companies had no immediate comment.